Table 1.
Baseline characteristics of patients in the drug treatment and catheter ablation groups.
| drug treatment (n = 41) | RFCA (n = 68) | CY (n = 30) | P-values | |
| Male/n (%) | 22 (53.66%) | 56 (82.35%) | 19 (63.33%) | .005a,b |
| Age/yr | 64.51 ± 8.12 | 58.68 ± 8.46 | 61.00 ± 7.62 | .002a,b |
| BMI (kg/m2) | – | 26.33 ± 3.32 | 26.09 ± 2.85 | .730 |
| recurrence /n (%) | – | 18 (26.47%) | 5 (16.67%) | .291 |
| Persistent AF/n (%) | 22 (53.66%) | 16 (23.53%) | 6 (20.00%) | .001b |
| Hypertension/n (%) | 25 (60.98%) | 31 (45.59%) | 18 (60.00%) | .445 |
| Diabetes/n (%) | 14 (34.15%) | 13 (19.12%) | 5 (16.67%) | .127 |
| CHD/n (%) | 17 (41.46%) | 11 (16.18%) | 4 (13.33%) | .004b |
| Heart failure/n (%) | 10 (24.39%) | 10 (14.71%) | 6 (20.00%) | .209 |
| CHA2DS2-VASc score | 2 (0, 5) | 1 (0, 4) | 2 (0, 6) | .000a,b |
| HAS-BLED score | 2 (0, 4) | 1 (0, 4) | 1 (0, 3) | .008a,b |
| Time of operation /minutes | – | 150 (89, 239) | 100.5 (70, 245) | .000 |
| LA short axis/mm | 41 (30,68) | 39 (28, 53) | 40 (25, 48) | .232 |
| LVEF (%) | – | 63 (32, 75) | 62.5 (54, 73) | .997 |
| Heart rate | – | 70 (52, 120) | 70 (50, 95) | .957 |
| The course of disease/month | 12 (48) | 24 (40) | 36 (63) | .273 |
| Smoking/n (%) | 16 (39.02%) | 20 (29.41%) | 20 (29.41%) | .076 |
| Drinking/n (%) | 14 (34.15%) | 22 (32.35%) | 22 (32.35%) | .934 |
| Anticoagulant therapy/n (%) | 21 (51.22%) | 38 (55.88%) | 14 (46.67%) | .764 |
| Antithrombotic drugs /n (%) | 13 (31.71%) | 26 (38.24%) | 10 (33.33%) | .643 |
| Antihypertensive drugs/n (%) | 20 (48.78%) | 25 (36.76%) | 17 (56.67%) | .154 |
| Hypoglycemic agent /n (%) | 10 (24.39%) | 10 (14.71%) | 3 (10.00%) | .232 |
| Lipid-lowering drugs /n (%) | 12 (29.27%) | 22 (32.35%) | 9 (30.00%) | .937 |
| TICS-m score at baseline | 36.41 ± 3.03 | 36.90 ± 2.97 | 36.90 ± 2.97 | .647 |